Approval · Notice of Compliance 28002 · 2022
EPREX: Notice of Compliance 28002
Issued April 21, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28002
- Date
- April 21, 2022
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EPREX | Not yet assigned | — |
Medicinal ingredients
- EPOETIN ALFA 1,000 UNIT per 0.5ML
- EPOETIN ALFA 2,000 UNIT per 0.5ML
- EPOETIN ALFA 3,000 UNIT per 0.3ML
- EPOETIN ALFA 4,000 UNIT per 0.4ML
- EPOETIN ALFA 5,000 UNIT per 0.5ML
- EPOETIN ALFA 6,000 UNIT per 0.6ML
- EPOETIN ALFA 8,000 UNIT per 0.8ML
- EPOETIN ALFA 10,000 UNIT per ML
- EPOETIN ALFA 20,000 UNIT per 0.5ML
- EPOETIN ALFA 30,000 UNIT per 0.75ML
- EPOETIN ALFA 40,000 UNIT per ML